<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207128</url>
  </required_header>
  <id_info>
    <org_study_id>UARK 2010-14</org_study_id>
    <nct_id>NCT01207128</nct_id>
  </id_info>
  <brief_title>Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis</brief_title>
  <official_title>A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the therapeutic effectiveness of combination&#xD;
      antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo&#xD;
      equivalent as primary therapy for invasive aspergillosis (IA) in patients with hematological&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous&#xD;
      (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the&#xD;
      first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be&#xD;
      switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and&#xD;
      gastrointestinal functions are intact.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    None enrolled&#xD;
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>maximum 6 weeks</time_frame>
    <description>Response is defined as normalization of the serum Aspergillus galactomannan index (GMI)values (first normal GMI value is considered day of response).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Voriconazole, Micafungin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voriconazole+Micafungin or Voriconazole+Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Voriconazole+Micafungin or Voriconazole+Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole, micafungin</intervention_name>
    <description>Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.</description>
    <arm_group_label>Voriconazole, Micafungin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient or legally authorized representative has signed an informed&#xD;
             consent/assent.&#xD;
&#xD;
             Assent will be obtained as required by the UAMS IRB.&#xD;
&#xD;
          2. The patient has a diagnosis of proven or probable invasive aspergillosis and with&#xD;
             positive Aspergillus GM index (â‰¥0.5 ng/ml) provide the patient is not receiving&#xD;
             antibiotics, such as piperacillin-tazobactam, that are known to cause false positive&#xD;
             GMI&#xD;
&#xD;
          3. The patient is 18 years of age or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient is being treated with an unlicensed investigational drug for&#xD;
             aspergillosis.&#xD;
&#xD;
          2. The patient has been administered an antifungal agent (voriconazole, itraconazole,&#xD;
             posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B, or lipid&#xD;
             formulation of amphotericin B) for &gt; 7 days immediately prior to randomization for&#xD;
             treatment of the Probable, or Proven invasive aspergillosis for which the patient is&#xD;
             being enrolled.&#xD;
&#xD;
          3. Patient has invasive aspergillosis but with negative Aspergillus GM index.&#xD;
&#xD;
          4. The patient is pregnant or lactating. If the patient is female and of childbearing&#xD;
             potential, the patient must have a negative pregnancy test and avoid becoming pregnant&#xD;
             while receiving study drug. A pregnancy test should be performed within 14 days prior&#xD;
             to the first dose of study drug.&#xD;
&#xD;
          5. The patient has alkaline phosphatase, ALT, AST or total bilirubin greater than five&#xD;
             times the upper limit of normal.&#xD;
&#xD;
          6. The patient has hepatic cirrhosis.&#xD;
&#xD;
          7. Patients with creatinine &gt; 3 will be enrolled only if able to receive oral&#xD;
             voriconazole (specify oral loading dose is 6 mg/kg PO Q 12 hours for 24 hours) then&#xD;
             oral maintenance 200 mg PO q 12 hours).&#xD;
&#xD;
          8. The patient is on artificial ventilation, and unlikely to be extubated within 24 hours&#xD;
             of study entry.&#xD;
&#xD;
          9. The patient has a history of allergy, hypersensitivity, or any serious reaction to the&#xD;
             azole or echinocandin class of antifungal agents.&#xD;
&#xD;
         10. The patient has previously enrolled into this study.&#xD;
&#xD;
         11. The patient has a concomitant medical condition, which in the opinion of the&#xD;
             Investigator may create an unacceptable additional risk.&#xD;
&#xD;
         12. The patient has an active microbiologically-documented deep infection due to a&#xD;
             non-Aspergillus mold.&#xD;
&#xD;
         13. The patient has a life expectancy of less than seven days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Anaissie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAMS</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2010</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

